Unique ID issued by UMIN | UMIN000045225 |
---|---|
Receipt number | R000051662 |
Scientific Title | Exploratory clinical study on the suppressive effect of the peptide on postprandial blood glucose level |
Date of disclosure of the study information | 2021/08/27 |
Last modified on | 2022/04/27 11:42:50 |
Exploratory clinical study on the suppressive effect of the peptide on postprandial blood glucose level
Suppressive effect of the peptide on postprandial blood glucose level
Exploratory clinical study on the suppressive effect of the peptide on postprandial blood glucose level
Suppressive effect of the peptide on postprandial blood glucose level
Japan |
Not applicable
Adult |
Others
NO
To evaluate the suppressive effect of the peptide on postprandial blood glucose level.
Efficacy
Area under the curve of blood glucose levels (0-120 min)
Postprandial blood glucose levels (each time point), Cmax of blood glucose level, Tmax of blood glucose level, insulin levels (0, 30 min), insulinogenic index
Interventional
Cross-over
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Treatment
Food |
A single intake of peptide food
A single intake of placebo food
20 | years-old | <= |
65 | years-old | > |
Male and Female
1) Subjects aged 20 years old or more and less than 65 years old.
2) Subjects whose fasting blood glucose levels are 125 mg/dL or less, and 2-h postprandial blood glucose levels are 199 mg/dL or less.
3) Subjects who have received a full explanation of the study, understand its contents, and have given their written informed consent to participate in the study.
1) Subjects who are undergoing continuous medical treatment.
2) Subjects who regularly take Foods for Specified Health Uses, Foods with Function Claims, health foods, etc., which may affect the study, and who can not stop taking them during the study period.
3) Subjects who smoke 20 cigarettes or more per day.
4) Subjects with BMI of 30.0 kg/m2 or more.
5) Subjects who have difficulty in blood collection.
6) Subjects who are pregnant, planning to become pregnant, or lactating.
7) Subjects who have a past or current history of serious diseases of the heart, liver, kidney, digestive organs, etc.
8) Subjects who excessively take alcohol (60 g/day or more).
9) Subjects who have serious allergies to medicines and foods (especially eggs, wheat, and dairy products).
10) Subjects who are currently participating in another clinical trial of a drug or food, or participated in that trial within 4 weeks, or plan to participate in that trial after giving informed consent to participate in this trial.
11) Subjects who have donated over 200 mL of blood within 1 month and over 400 mL within 3 months before beginning this study.
12) Subjects who are judged as ineligible to participate in this study by the principal investigator or sub-investigator.
18
1st name | Shukuko |
Middle name | |
Last name | EBIHARA |
Chiyoda Paramedical Care Clinic
Doctor
101-0047
2F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan
03-5297-5548
cpcc-contact@cpcc.co.jp
1st name | Masanori |
Middle name | |
Last name | NUMA |
CPCC Company Limited
Clinical Planning Department
101-0047
4F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan
03-5297-3112
cpcc-contact@cpcc.co.jp
CPCC Company Limited
Morinaga Milk Industry Co., Ltd.
Profit organization
Institutional Review Board of Chiyoda Paramedical Care Clinic
2F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan
03-5297-5548
IRB@cpcc.co.jp
NO
2021 | Year | 08 | Month | 27 | Day |
Unpublished
Completed
2021 | Year | 07 | Month | 19 | Day |
2021 | Year | 07 | Month | 16 | Day |
2021 | Year | 08 | Month | 27 | Day |
2021 | Year | 10 | Month | 11 | Day |
2021 | Year | 08 | Month | 23 | Day |
2022 | Year | 04 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051662